Genmab — April 2020

[Solsen]

Can we use that ?

[E_L]

i am not sure lol, actually the markets tank the minute you write this

[E_L]

[RTRS] - REMDESIVIR, HAS FLOPPED IN ITS FIRST RANDOMISED CLINICAL TRIAL, ACCORDING TO DRAFT DOCUMENTS PUBLISHED ACCIDENTALLY BY THE WHO - FT

[E_L]

Gilead halted?

[E_L]

[RTRS] - GILEAD WARNED THAT THE DRAFT DOCUMENT POSTED ACCIDENTALLY BY WHO INCLUDED “INAPPROPRIATE CHARACTERISATIONS OF THE STUDY”- FT

[E_L]

GILD back open and recovering most of 7%
loss

[troldmanden]

Den kan de da ikke spinde rundt til noget positivt

[Solsen]

Svar på det retrospektive skriv fra forleden, der anførte højere dødelighed i HCQ grupperne https://www.mediterranee-infection.com/wp-content/uploads/2020/04/Response-to-Magagnoli.pdf

[Solsen]

GILD has to be quick to report, if WHO knows something.

[E_L]

i read it was an article that was not yet peer-reveiwed and immediately removed from their site. i think it is on the chinese trial, which may not the best triel to judge on anyway

[E_L]

so many people that have no clue suddenly think they are experts and judge and trade on rumours.... not an easy market...

[E_L]

one should only trade on Genmab rumours from @GeorgeBest

[E_L]

anohter mistake by WHO by the way, not very impressed with this organisation the last few months...

[GeorgeBest]

Hope we will also get facts soon

[E_L]

[Solsen]

Agree on WHO...

[Bulder]

(Bloomberg) -- Here is the full text of an emailed statement from Gilead Sciences Inc. after reports that the company’s experimental drug being tested in severe Covid-19 patients failed to show a positive result in a Chinese trial.
forts.

[Bulder]

We regret that the WHO prematurely posted information regarding the study, which has since been removed. The investigators in this study did not provide permission for publication of results. Furthermore, we believe the post included inappropriate characterizations of the study. forts.

[Bulder]

Importantly, because this study was terminated early due to low enrollment, it was underpowered to enable statistically meaningful conclusions. As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease. forts.

[Bulder]

We understand the available data have been submitted for peer-reviewed publication, which will provide more detailed information from this study in the near future. There are multiple ongoing Phase 3 studies that are designed to provide the additional data needed to determine the potential for remdesivir as a treatment for COVID-19. These studies will help inform whom to treat, when to treat and how long to treat with remdesivir. forts.